(Q45369749)

English

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

scientific article published on 19 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 December 2017

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts (English)

1 reference

Europe PubMed Central

13 December 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Akihiro Tamori

1

1 reference

Europe PubMed Central

13 December 2017

Tatsuya Koike

2

1 reference

Europe PubMed Central

13 December 2017

Hitoshi Goto

3

1 reference

Europe PubMed Central

13 December 2017

Shigeyuki Wakitani

4

1 reference

Europe PubMed Central

13 December 2017

Masahiro Tada

5

1 reference

Europe PubMed Central

13 December 2017

Hiroyasu Morikawa

6

1 reference

Europe PubMed Central

13 December 2017

Masaru Enomoto

7

1 reference

Europe PubMed Central

13 December 2017

Masaaki Inaba

8

1 reference

Europe PubMed Central

13 December 2017

Tatsuya Nakatani

9

1 reference

Europe PubMed Central

13 December 2017

Masayuki Hino

10

1 reference

Europe PubMed Central

13 December 2017

Norifumi Kawada

11

1 reference

Europe PubMed Central

13 December 2017

publication date

19 January 2011

1 reference

Europe PubMed Central

13 December 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

13 December 2017

46

1 reference

Europe PubMed Central

13 December 2017

4

1 reference

Europe PubMed Central

13 December 2017

556-564

1 reference

Europe PubMed Central

13 December 2017

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Reactivation of hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Chronic viral hepatitis and TNF-alpha blockade

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Prophylaxis and treatment of hepatitis B in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0367-5

21 January 2018

Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-010-0367-5

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45369749&oldid=2075919617"